HMOX1 and chronic myelogenous leukemia, BCR-ABL1 positive: Further work showed that targeting HO-1 activity concurrently with imatinib treatment induced growth arrest in CML patient cells and imatinib-resistant CML cells were killed by blocking HO-1 activity.